Trial Profile
Phase 2 study of Namacizumab in patients with non-alcoholic fatty liver disease (NAFLD)
Status:
Planning
Phase of Trial:
Phase II
Latest Information Update: 07 Nov 2023
Price :
$35
*
At a glance
- Drugs Nimacimab (Primary)
- Indications Non-alcoholic fatty liver disease
- Focus Therapeutic Use
- 16 Jan 2017 New trial record